PATENT CLAIM ANALYSIS

Application Number: 15901439
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-12
Patent Classification: ["514", "397000"]

Abstract:
The present disclosure comprises a method for administering 2,3-dihydro-isoindole-1-one compound or a pharmaceutically acceptable salt, ester, solvate and/or prodrug thereof, for the treatment of hematological cancers such as acute myeloid leukemia (AML). The present disclosure further relates to reducing or inhibiting cell-proliferation which is activated by wild-type or mutated Fms-like tyrosine kinase-3 receptor (FLT3). The present disclosure further relates to a method of inhibiting or reducing abnormal (e.g., overexpressed) wild-type or mutated BTK activity or expression in a subject in need thereof.

Claim (Index 205):
The method of  claim 201 , wherein the at least one point mutation is on one or more amino acid residue positions selected from the group consisting of 686, 687, 688, 689, 690, 691, 692, 693, 694, 695, and 696.

Metadata:
- Claim Count in Document: 87.0
- Percentile: 88.0
- Lexical Diversity: 1.58333
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15581736', '14053011', '15101240', '14820434', '14671613']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8145352687025041
- 35 USC 102 Novelty (BERT): 0.5335582335741926
- Combined Prediction Score: 0.786437565189673
- Mean Citation Score: 348.025778
- Max Citation Score: 372.31412
- Similarity Product: 262.12773566316133

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test